Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

NCT ID: NCT03836482

Last Updated: 2025-09-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2027-08-31

Brief Summary

Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system but also the renal, neuroendocrine, and immune systems. No effective therapy is currently available to treat the most severe subset of CHF patients that have progressed to acute decompensated HF. An innovative approach to reduce the cardio-depressant effects associated with the chronic inflammatory state of CHF may provide a breakthrough for this disorder. This proposal will evaluate the safety and probable benefit to improve cardiac or renal function with an immunomodulatory device to bridge patients to Left Ventricular Assist Device (LVAD) implantation who were previously deemed ineligible for this life sustaining procedure. The Selective Cytopheretic Device (SCD) is an immuno-regulating, extracorporeal membrane device targeted to modulate the cardiodepressant effects assocaited with CHF. SCD is a platform technology focused on immunomodulation of acute and chronic inflammation associated with acute and chronic organ dysfunction. SCD membranes selectively sequester activated systemic leukocytes as they flow through the cartridge via an extracorporeal circuit. Pre-clinical results show that SCD treatment results in a 25% improvement in ejection fraction in a canine CHF model.

This study will enroll 20 patients across up to 5 clinical sites to evaluate the safety and initial efficacy data of SCD treatment in this indication. Patients will receive 4-hour daily SCD treatment for up to 6 days, followed by 6 months of follow up.

Conditions

Acute on Chronic Systolic Congestive Heart Failure; Cardiorenal Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Selective Cytopheretic Device

Group Type: EXPERIMENTAL

Selective Cytopheretic Device

Intervention Type: DEVICE

Treatment will be delivered for 4 hours a day for up to 6 consecutive days.

Interventions

Selective Cytopheretic Device

Treatment will be delivered for 4 hours a day for up to 6 consecutive days.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age of 18 years and older.

2. Evidence of systemic inflammation: blood CRP ≥ 4.5 mg/L or IL-6 ≥ 5.0 pg/ml or neutrophil to lymphocyte ratio ≥3.0.

3. Primary hospitalization for acute decompensated chronic systolic heart failure.

4. Potential LVAD candidate with:

a) Left ventricular ejection fraction ≤25% (for potential destination therapy) or ≤ 35% (for potential bridge to transplantation) as confirmed by baseline imaging procedure b) NYHA class IIIB or IV chronic (≤ 90 days) systolic heart failure, with failure to respond to optimal medical therapy (beta blocker, ACE inhibitor or ARB or valsartan/sacubitril, aldosterone antagonist, SGLT2i, unless not tolerated or contraindicated, and loop diuretic, as needed) for 45 of the last 60 days c) Known previous peak exercise oxygen consumption < 14 mL/Kg/min or if unable to exercise, dependent on an intra-aortic balloon pump, short-term mechanical circulatory support device or intravenous inotropes unless inotropes contraindicated for clinical reasons (e.g., ventricular arrhythmias)

5. Baseline eGFR** ≥ 40 ml/min/1.73 m2 (baseline defined as the highest known eGFR within 90 days of study enrollment)

6. At least one of the following two criteria:

1. Severe right ventricular failure (RVF), defined as meeting at least 2 of the following 4 criteria -Central venous pressure > 16 mmHg

-Central venous pressure/Pulmonary wedge pressure >0.65

-Right ventricular stroke work index < 300 mmHg * ml/m2

-Pulmonary artery pulsatility index (PAPi) < 2,

2. Worsening renal failure (WRF), defined for the purposes of this study as -Increase serum creatinine ≥ 0.5 mg/dL from baseline (baseline defined as the lowest known serum creatinine within 90 days of study enrollment) AND

• eGFR** ≤ 30 ml/min/1.73 m2 based on serum creatinine at enrollment*** AND
• Cardiorenal syndrome is the most likely explanation for WRF AND
• Intolerant or inadequately responsive to standard of care diuretic therapy, defined as persistent signs and/or symptoms of congestion (e.g., peripheral edema, dyspnea, pulmonary rales, neck vein distension) or minimal net volume removal in a 24-hour period despite optimal medical therapy including intravenous diuretic therapy and an estimated need for >5kg fluid removal.

1. Optimal intravenous diuretic therapy is defined as:

1. Furosemide equivalent total daily dose of 240mg

2. Furosemide equivalent dose given either as a single or multiple intravenous bolus or continuous infusion

3. A furosemide equivalent total daily dose <240mg if the dose has resulted in >3000 mL urine output/24 hours.

7. PA catheter in place at the time of enrollment

8. PCW ≥ 20 mmHg

• eGFR calculated using the CKD-EPI Creatinine Equation *** Recognizing that this is not a steady state creatinine

Exclusion Criteria

1. Any clear contraindication to LVAD therapy that is unlikely to resolve with improvement in renal function and volume status

2. Prior sensitivity to dialysis device components

3. Active bacteremia

4. Temperature ≥ 101.5 F or WBC ≥ 10,000 K/uL or any patient with suspected systemic infection.

5. Metastatic malignancy requiring palliative chemo, biologic, or radiation

6. Need for intravenous vasopressor (i.e., phenylephrine, vasopressin), intravenous vasoconstricting inotrope (i.e., norepinephrine or epinephrine) or dopamine > 3 mcg/kg/min. (Note: use of vasodilating inotropes [i.e., dobutamine and milrinone] or dopamine at ≤ 3 mcg/kg/min will not preclude study inclusion)

7. Patients requiring mechanical ventilatory support

8. Patients requiring total parenteral nutrition during the treatment period

9. Persistent SBP < 80 mmHg

10. WBC < 4000 K/uL

11. Platelets < 100,000K/uL

12. Serum creatinine > 4 mg/dL or receiving dialysis / CRRT

13. Acute coronary syndrome within the past month

14. Women who are pregnant, breastfeeding a child, or trying to become pregnant

15. Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical studies where only measurements and/or samples are taken (i.e., no test device or test drug used) are allowed to participate

16. Use of any other investigational drug or device within the previous 30 days. Patients who participated in a clinical study where only measurements and/or samples are taken (i.e., no test device or drug used) are allowed to participate.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

University of Michigan

OTHER

Sponsor Role: collaborator

Innovative BioTherapies (IBT)

INDUSTRY

Sponsor Role: collaborator

SeaStar Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1R44HL170779-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

SCD-CRS-01

Identifier Type: -

Identifier Source: org_study_id